We recently published a list of 10 Firms Kick Off Monday Leading Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms that kick off Monday leading gains.

The stock market kicked off the week’s trading on a positive note, with all main indices finishing in the green territory, as economies took a pause from their tariff war, while investors breathed a sigh of relief on the February retail sales report which didn’t come worse.

According to the latest figures, retail sales rose 0.2 percent, albeit below the 0.6 percent as expected by analysts. Excluding autos, sales are up by 0.3 percent, in line with economists’ expectations.

Following the news, the Dow Jones clocked in a 0.85-percent gain, followed by the S&P 500 with 0.64 percent, and the tech-heavy Nasdaq with 0.31 percent.

Meanwhile, 10 companies that led the rally posted modest gains as fresh company developments sparked investor buying. In this article, we have listed Monday’s 10 top performers and detailed the reasons behind their gains.

To come up with the list, we considered only the stocks with $2 billion market capitalization and $5 million in trading volume.

A pharmacist in a hospital pharmacy stands next to a row of various drug containers.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose for a second straight day on Monday, adding 7.72 percent to close at $6.84 apiece as investors repositioned portfolios while all eyes were on the ongoing NVIDIA GTC event.

It can be recalled that Recursion Pharmaceuticals (NASDAQ:RXRX) was one of the few companies in which giant chipmaker Nvidia Corp. (NASDAQ:NVDA) invested. In a regulatory filing last month, NVDA’s holdings showed that it retained its 7.7-million holdings in RXRX, while exiting firms, including SoundHound AI.

The news represented a vote of confidence not just for NVDA but among small investors.

RXRX is a clinical-stage biotechnology company leading the space by decoding biology to industrialize drug discovery.

Overall, RXRX ranks 9th on our list of firms that kick off Monday leading gains. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as RXRX but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires

Disclosure: None. This article is originally published at Insider Monkey.